| Bioactivity | BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels[1]. |
| Target | GABA- and glutamate-gated chloride channels |
| In Vivo | BTG 1640 (ABIO-08/01) 在小鼠和大鼠焦虑模型中单次腹腔注射和单次口服给药（灌胃）后，以极低剂量显示活性。长期给药既没有导致耐受性的发展，也没有在突然停止治疗后出现戒断症状[2]。 |
| Name | BTG 1640 |
| CAS | 152538-59-5 |
| Formula | C15H19NO2 |
| Molar Mass | 245.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Correll CU, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023 Feb;22(1):48-74. [2]. Saletu-Zyhlarz GM, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. Neuropsychobiology. 2009;59(2):100-9. |